LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Stock List・Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc

Closed

Sector Healthcare

467.89 0.07

Buy Sell

Overview

Share price change

24h

Current

Min

467.08

Max

470.91

Key metrics
By Trading Economics
Income	-4.7B -3.6B
Sales	-40M 2.7B
P/E Sector Avg	30.09 103.001
EPS	-12.83
Profit margin	-135.608
Employees	5,400
EBITDA	263M 1.3B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+9.17 upside

Dividends
By Dow Jones
Next Earnings	4 Nov 2024

Market Stats
By TradingEconomics
Market Cap	128B
Previous open	467.82
Previous close	467.89

News Sentiment

By Acuity

69%

31%

311 / 365 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

463.41 / 481.19 Support & Resistance

Vertex Pharmaceuticals Inc Chart

Related News

1 Aug 2024, 20:45 UTC

Earnings

Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

6 May 2024, 20:37 UTC

Earnings

Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug

10 Apr 2024, 22:48 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition

10 Apr 2024, 21:40 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.

10 Apr 2024, 21:24 UTC

Acquisitions, Mergers, Takeovers

Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion -- Update

10 Apr 2024, 20:30 UTC

Peer Comparison

Price change

Vertex Pharmaceuticals Inc Forecast

Price Target

By TipRanks

9.17% upside

12 Months Forecast

Average 510.9 USD 9.17%

High 600 USD

Low 325 USD

Based on 23 Wall Street analysts offering 12 month price targets forVertex Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

23 ratings

Buy

Hold

Sell

Based on 23 analysts giving stock ratings to Vertex Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

463.41 / 481.19Support & Resistance

Recent bearish events outweigh bullish events.

There are no events.

Sentiment

By Acuity

311 / 365 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.